Response Rate to the 3rd and 4th Doses of BNT162b2 Vaccine in Cancer Patients Administered with Active Anti-Neoplastic Treatments
Authors:
- Abed AgbaryaAbed Agbarya
- Ina SarelISIna Sarel
- Tomer Ziv-BaranTZTomer Ziv-Baran
- Orna SchwartzOSOrna Schwartz
- Mohammad Sheikh-AhmadMohammad Sheikh-Ahmad
- Leonard SaieghLSLeonard Saiegh
- Forat SwaidFSForat Swaid
- Yelena ShechtmanYSYelena Shechtman
- Ella KozlenerEKElla Kozlener
- Rasha KhouryRKRasha Khoury
- Urska JanzicUrska Janzic
- Asala Abu-AhmadAAAsala Abu-Ahmad
Preprint
- 29 August 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response of administering the 3rd and 4th vaccine doses to can-cer patients receiving active anti-neoplastic treatment. 142 patients have received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients have received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients after three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients after two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38-42.12), p=0.02 and 17.15 (95% CI 5.01-58.7), p<0.01, respective-ly). Unlike the response after two doses, the 3rd and 4th BNT162b2 vaccine booster doses, had an increased efficacy of 95-100% in cancer patients while on active treatment. This result could be explained by different mechanisms including the development of memory B cells.Keywords
All Related Versions
This publication has 55 references indexed in Scilit:
- Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodiesEuropean Journal of Internal Medicine, 2022
- Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?European Journal of Cancer, 2022
- Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patientsCancer Reports, 2022
- Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort studyESMO Open, 2022
- Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary dataJournal of Clinical Virology, 2021
- Administration of COVID-19 vaccines in immunocompromised patientsInternational Immunopharmacology, 2021
- Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273JAMA, 2021
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for CancerJAMA Oncology, 2021
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 DosesJAMA, 2021
- Infectious Disease Complications in Patients with CancerCritical Care Clinics, 2021